LIC MF Healthcare Fund
The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors.
Growthvine rating: 3/5 — ranked #24 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹32.84 (as of 2026-10-01) |
|---|
| AUM | ₹98 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dhaval Sangoi |
|---|
| Exit load | For units in excess of 12% of the investment, 1% will be charged for redemption within 90 days |
|---|
Performance & risk
| Sharpe ratio | 1.01 |
|---|
| Standard deviation | 15.86% |
|---|
| Max drawdown | −15.35% |
|---|
| Alpha | -1.28 |
|---|
| Beta | 0.93 |
|---|
Over 5 years, captured 89.7% of NIFTY Pharma's upside and 84.1% of its downside.
Market cap allocation
| Large cap | 32.5% |
|---|
| Mid cap | 33.1% |
|---|
| Small cap | 34.4% |
|---|
Concentration
| Top 5 holdings | 38.4% |
|---|
| Top 10 holdings | 62.8% |
|---|
| Total holdings | 23 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 10.1%
- Divis Laboratories Ltd. — 9.3%
- Torrent Pharmaceuticals Ltd. — 6.4%
- Neuland Laboratories Limited. — 6.4%
- Apollo Hospitals Enterprises Ltd. — 6.2%
- Navin Fluorine International Limited — 5.7%
- Aurobindo Pharma Ltd. — 5.2%
- Aster DM Healthcare Limited — 4.8%
- Zydus Lifesciences Limited — 4.8%
- Gland Pharma Limited — 3.9%
Top sectors
- Pharma & Biotech — 62.7%
- Healthcare — 30.1%
- Chemicals — 5.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 12.8% | Q1 (Top) | #12 of 76 |
| 2025 | −4.4% | Q4 (Bottom) | #54 of 69 |
| 2024 | 42.1% | Q1 (Top) | #6 of 58 |